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Dic(9;20)(p13;q11) was first described as a nonrandom chromo-
some abnormality in B-cell precursor acute lymphoblastic
leukaemia (BCP ALL) in the mid 1990s,1,2 and 71 dic(9;20)-
positive cases have since then been reported.3–5 Approximately
90% of these cases were children or adolescents, with dic(9;20)
occurring in about 2% of childhood BCP ALL.6 The recent review
by Forestier et al.5 describes that dic(9;20)-leukaemias are of B-
cell precursor immunophenotype, never have a high hyperdiploid
modal number, show a female predominance, and have a
significant age incidence peak at 3 years. Most patients are
allocated to non-standard risk treatment arms due to high WBC
(median 24 109/l) and a relatively high frequency of CNS
disease or other extra-medullary leukaemia (EML) at diagnosis.
The prognostic implications of dic(9;20) are to a large extent
unknown. A relatively large proportion of the relapses reported in
the literature have been extra-medullary, and post-relapse
treatment including block therapy has been successful in several
patients, as illustrated by a p-EFS of 0.62 and a predicted overall
survival of 0.82 at 5 years for the 24 Nordic cases.5
The optimal treatment strategy for children with dic(9;20)-
positive BCP ALL is not known. Test of cellular drug resistance
in vitro might help to elucidate this problem, and we have
therefore analysed samples from patients with and without
dic(9;20) to see if this aberration is associated with a specific
drug sensitivity profile. To our knowledge, no such data have
been published so far.
Leukaemic cells from bone marrow or peripheral blood of
children (aged 1–17 years) with newly diagnosed BCP ALL
were used in this study. Nordic centres for paediatric oncology
participated and provided samples for test of in vitro drug
resistance from 719 patients between January 1996
and December 2006. The patients were representative of all
children in this age group diagnosed with BCP ALL in the
Nordic countries during the study period, as evidenced by
similarities in sex, age, WBC count at diagnosis, immuno-
phenotype, cytogenetics and p-DFS (not shown). During this
time period, two closely related protocols have been used,
NOPHO-ALL-1992 and NOPHO-ALL-2000, the former de-
scribed in detail by Gustafsson et al.7 Dic(9;20) has not been
a risk stratifying aberration in any of the two protocols. Instead,
the choice of treatment intensity for patients with dic(9;20)-
positive ALL was made according to age, WBC count, the
presence of EML and morphologic response during induction
therapy.
Chromosome banding analyses were performed using
standard methods in 15 cytogenetic laboratories in the Nordic
countries, and all abnormal karyotypes have annually been
centrally reviewed (since 1996 in Sweden and since 2000 in all
five Nordic countries). To retrieve as many dic(9;20)-positive
ALL as possible, cases with either probable dic(9;20) or with
abnormalities suggesting the presence of this aberration, such as
monosomy 20 and deletion of 9p,3 and with metaphase cells in
fixative, surplus from the initial cytogenetic investigations, were
screened by FISH using the LSI 9p21/CEP-9 dual-colour and
the CEP-20 probes according to the manufacturer’s instructions
(Vysis, Stockholm, Sweden). In total, 37 such cases were
analysed. The same FISH probes were also applied to confirmed
dic(9;20)-positive ALL.5
Leukaemic cells were tested by the fluorometric microculture
cytotoxicity assay (FMCA), a rapid and reproducible method
for determination of in vitro drug sensitivity. It is based on
the measurement of fluorescence generated from hydrolysis of
fluorescein diacetate to fluorescein by cells with intact plasma
membranes and has been described in detail.8,9 Drugs were
tested in triplicate. Six wells without drugs served as controls
and six wells containing culture medium only served as blanks.
The results are presented as survival index (SI), defined as
fluorescence in test wells/fluorescence in control wells (blank
values subtracted)  100. Thus, a low numerical value indicates
high sensitivity to the cytotoxic effect of the drug.
Cytotoxic drugs were obtained from commercial sources and
tested at empirically derived concentrations, chosen to produce
a large scatter of SI values among the samples (see Table 2).
These concentrations were adopted from previous studies of
leukaemic cells.8
Non-parametric statistical methods were used throughout.
The SPSS 14.0 software package was used for the calculations.
All analyses were two-tailed and the level of statistical
significance was set at Po0.05. Local ethics committees
approved the study.
The FMCA was successful in 546 (76%) of the samples, and
the reasons for failure were low proportion of lymphoblasts in
control wells after incubation (n¼ 21); low signal-to-noise ratio
(n¼ 108); high coefficient of variation in controls (n¼ 29) and
other technical problems (n¼ 15).
Eleven out of the 546 samples successfully tested for in vitro
drug resistance were diagnosed with dic(9;20). Table 1 shows
the distribution of some important clinical and biological
parameters within this group, as compared with the 24 Nordic
cases described in a recent publication, and literature data from
previous publications. A low median age of 3 years, female
preponderance, high WBC count at diagnosis and a prevalence
of 2% in our patient population, are characteristics that agree
very well with published data.
Table 2 shows the in vitro drug resistance in samples from
patients with or without dic(9;20). The dic(9;20)-positive
samples were significantly more sensitive to asparaginase,
cytarabine, dexamethasone and prednisolone, and there was a
nonsignificant trend in the same direction also for the other
drugs tested.
The next step in the data analysis was to exclude patients with
other chromosomal aberrations known to be of prognostic
significance and present exclusively in the dic(9;20)-negative
group: high hyperploidy (n¼ 184), t(12;21)(p13;q22) (n¼ 109),
t(9;22)(q34;q11) (n¼ 12), t(1;19)(q23;p13) (n¼ 19) and 11q23
translocations (n¼ 10). As shown in Table 3, dic(9;20)-positive
samples were much more sensitive to cytarabine and
prednisolone than negative samples, with significant differences
also for asparaginase, dexamethasone and 6-thioguanine.
Figures 1a–c show data for dic(9;20) compared with major
cytogenetic subgroups in this material for three important ALL
drugs. Dic(9;20) and t(1;19) samples were clearly among the
most sensitive to cytarabine and prednisolone. A different
pattern was seen with vincristine, where t(1;19) samples had a
median SI of 19, whereas all other subgroups, including
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dic(9;20), had median values between 36 and 53. When the
dic(9;20) and t(1;19) groups were compared, similar SI values
were found for most of the 10 drugs, except that the t(1;19)
samples were significantly more sensitive to vincristine
(P¼ 0.005).
At the latest follow-up in January 2008, one patient with
dic(9;20), initially treated as standard risk, had relapsed with
EML in CNS 2.5 years after diagnosis. The patient is in second
remission 12 months later. The median follow-up time for
dic(9;20) patients in continuous complete remission is 50
months (range 24–135 months), so further relapses may still
occur.
We have previously reported data on in vitro cellular drug
resistance in 370 Nordic children with ALL and correlated the
findings to risk group.10 The specific drug sensitivity profile of two
cytogenetic subgroups, t(12;21) and t(1;19), has also been
Table 1 Characteristics of children with dic(9;20) ALL tested for in vitro cellular drug resistance (n¼11) compared with the whole Nordic
material (n¼ 24) and other published cases of dic(9;20)-positive BCP ALL (n¼47)
In vitro tested
N¼11
Whole Nordic material
N¼24
Literature data
N¼ 47
Age (years)
Median 3.3 3 3
Range 1.3–14.1 0–15 0–17
Female/male (quotient) 2.7 1.7 2.1
Percentage of BCP ALL 2.0 1.3 2
WBC (109/l)
Median 34 24 24
Range 2.6–121 0.9–303 2.3–536
Risk group (n)
SR 3 5
IR 3 9
HR 5 9
Infant 0 1
Treatment protocol
NOPHO ALL-92 4 11
NOPHO ALL-2000 7 12
Interfant 99 1
Follow-up time (months)
Median 50 61
Range 24–135 24–135
Relapse rate (%) 9 29 25
Abbreviations: ALL, acute lymphoblastic leukaemia; BCP ALL, B-cell precursor acute lymphoblastic leukaemia; HR, high risk; IR, intermediate risk;
SR, standard risk.
The 11 patients tested for in vitro drug resistance are part of the Nordic material (n¼ 24).
Data for the Nordic group and literature data were summarized by Forestier et al.5
Follow-up time for patients in continuous complete remission.
Table 2 In vitro drug resistance in children with dic(9;21) (n¼11) compared with other children with BCP ALL (n¼535)
Drug Concentration Dic(9;20) All other BCP ALL
Median (25th–75th) Median (25th–75th) P-value
Amsacrine 1 21 (16–35) 27 (16–43) 0.42
Asparaginase 1 39 (27–56) 67 (50–82) 0.017
Cytarabine 0.5 35 (28–41) 56 (39–72) 0.005
Dexamethasone 1.4 26 (16–50) 50 (35–66) 0.025
Doxorubicin 0.5 19 (12–52) 30 (17–44) 0.33
Etoposide 5 25 (19–80) 37 (22–57) 0.64
Melphalane 2.5 16 (9–21) 28 (18–38)
Prednisolone 50 20 (16–42) 47 (31–61) 0.010
Vincristine 0.5 36 (31–66) 50 (34–71) 0.56
6-Thioguanine 10 23 (17–40) 38 (22–55) 0.12
Abbreviations: BCP ALL, B-cell precursor acute lymphoblastic leukaemia; SI, survival index.
Concentrations of the drugs are in microgram per millilitre, except for asparaginase (units per millilitre).
Median and 25th–75th percentile SI values denote percentage of surviving cells compared with controls.
Only four dic(9;20)-positive samples were tested with melphalane.
P-values were determined by the Mann–Whitney U-test.
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described.11,12 These patients, together with new cases added after
the publication of the reports, here form the cohort of 535 BCP ALL
patients, which is compared with the eleven cases with dic(9;20).
Our main finding was that tumour cells with the dic(9;20)-
aberration were significantly more sensitive to asparaginase,
cytarabine, dexamethasone and prednisolone, than other BCP
ALL samples. Although the number of dic(9;20)-positive patients
tested was limited, the findings were highly significant. The
difference between dic(9,20)-positive and dic(9,20)-negative
patients remained significant after elimination of unevenly
distributed other cytogenetic subsets, such as high hyperploidy,
t(1;19), t(9;22), t(12;21) and 11q23 translocations. One could
speculate that dic(9;20)-positive cells are generally more
susceptible to handling and various unspecific stimuli, thus
explaining the results, but this is strongly contradicted by the
finding that control cell survival was similar in the dic(9;20)-
positive and dic(9;20)-negative groups.
Any conclusions regarding clinical treatment based on in vitro
data must be drawn with great caution. Whether dic(9;20)
patients benefit from intensified therapy including high-dose
cytarabine, or from more extended treatment with asparaginase,
as suggested by this data, can only be demonstrated by clinical
trials. The fact that children with dic(9;20) have received
treatment of varying intensity in different treatment protocols
might help to answer the question of optimal therapy. To shed
some light on this the ‘Ponte di Legno’ Working Group has, at its
latest workshop in Atlanta in December 2007, initiated a
retrospective meta-analysis of survival data for patients with this
newly identified cytogenetic aberration.
Table 3 In vitro drug resistance in children with dic(9;20) (n¼ 11)
compared with other BCP ALL patients (n¼201) excluding high
hyperploidy, t(12;21), t(9;22), t(1;19) and 11q23 rearrangement
Drug Dic(9;20) Other BCP ALL
Median (25th–75th) Median (25th-75th) P-value
Amsacrine 21 (16–35) 26 (16–42) 0.49
Asparaginase 39 (27–56) 69 (55–89) 0.013
Cytarabine 35 (28–41) 65 (48–76) o0.001
Dexamethasone 26 (16–50) 51 (34–69) 0.029
Doxorubicin 19 (12–52) 33 (20–47) 0.20
Etoposide 25 (19–80) 35 (22–59) 0.73
Melphalane 16 (9–21) 31 (18–43)
Prednisolone 20 (16–42) 49 (33–65) 0.007
Vincristine 36 (31–66) 52 (37–73) 0.40
6-thioguanine 23 (17–40) 43 (30–61) 0.016
Abbreviations: BCP ALL, B-cell precursor acute lymphoblastic
leukaemia; SI, survival index.
The concentrations of the drugs are shown in Table 2.
Median and 25th–75th percentile SI values denote % surviving cells
compared to controls.
P-values were determined by the Mann–Whitney U-test.
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Figure 1 In vitro drug resistance in 11 children with dic(9;20)-positive ALL compared with other major cytogenetic subgroups. (a) cytarabine
0.5mg/ml, (b) prednisolone 50mg/ml and (c) vincristine 0.5 mg/ml. Dic(9;20) n¼11; t(1;19) n¼ 19, t(9;22) n¼ 12, HH (high hyperploidy with 451
chromosomes) n¼184, t(12;21) n¼ 109, other abn (other clonal abnormalities) n¼ 89, normal n¼ 70, no result n¼ 35. The box-and-whisker plot
shows median, first and third quartiles; whiskers extend to the highest and lowest value, excluding outliers, which are denoted by circles.
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In summary, we found that the presence of dic(9;20) in
childhood ALL was associated with low cellular drug resistance
to asparaginase, cytarabine and corticosteroids. These data
might help to understand the effect of different treatment
regimens and determine the most efficient therapy for this group
of patients.
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A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes
have stable disease
Leukemia (2009) 23, 212–214; doi:10.1038/leu.2008.260;
published online 25 September 2008
TP53 abnormalities consistently emerge as the most significant
adverse prognostic factor in multivariate analyses of both
prospective and retrospective studies in early and advanced
chronic lymphocytic leukaemia (CLL).1 In view of the higher
response rates often achieved with alemtuzumab-containing
regimens compared with alkylating agent and/or purine
analogue therapy2 and the possibility of long-term disease-free
survival following allogeneic transplantation in some patients,
there is an increasing consensus for screening for TP53
abnormalities in CLL patients who fulfil the International
Workshop on Chronic Lymphocytic Leukemia (IWCLL) recom-
mendations for initiating therapy. It has also been suggested that
the detection of a TP53 abnormality in early CLL should be an
indication for treatment with an alemtuzumab-containing
regimen.3 However, a small subset of patients with TP53
abnormalities pursue a benign clinical course.
Since 1994, we have examined fresh or dimethyl sulphoxide
frozen cells from CLL patients presenting to the Royal Bourne-
mouth Hospital, both for TP53 loss by fluorescence in situ
hybridization (FISH) and karyotypic abnormalities determined
by G-banding. Analysis of G-banded metaphases was from
peripheral blood lymphocyte cultures stimulated with Phorbol-
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